Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to dAMD
Phase 2
Not yet recruiting
- Conditions
- Non-Exudative (dry) Age-related Macular Degeneration (dAMD)
- Interventions
- Drug: EG-301Dietary Supplement: AREDS2 supplements
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Evergreen Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05170048
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
Phase 2
Not yet recruiting
- Conditions
- Advanced Endometrial Cancer
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Evergreen Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05106127
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Phase 3
Not yet recruiting
- Conditions
- Advanced Endometrial Cancer
- Interventions
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Evergreen Therapeutics, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT05077215
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
Phase 2
Withdrawn
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Evergreen Therapeutics, Inc.
- Registration Number
- NCT04561180
© Copyright 2025. All Rights Reserved by MedPath